KOHEN AVOCATS · PARIS, FRANCE
Roundup settlement: what the November 20 final approval means for payouts, appeals and opt-outs

Hassan Kohen is a Paris-based lawyer admitted to the Paris Bar (Avocat au Barreau de Paris). Initial strategic analysis: €80 incl. VAT, personal reply within 24 hours.

100% confidential · Legal professional privilege · No obligation

Article generated by artificial intelligence, through a process designed and supervised by the firm

Sources: U.S. court opinions and official U.S. government publications, read for this article

Maître Hassan KOHEN, avocat au Barreau de Paris
Hassan KOHEN
Attorney at the Paris Bar

Roundup settlement: what the November 20 final approval means for payouts, appeals and opt-outs

Speak to a lawyer 06 89 11 34 45

A Missouri state court granted final approval on November 20, 2026, to the nationwide class settlement meant to resolve current and future claims that exposure to Roundup weed killers caused non-Hodgkin lymphoma, according to a release Bayer published that day. The case is King v. Monsanto Co., No. 2622-CC00325, a class action filed on February 17, 2026, in the Circuit Court of the City of St. Louis to seek approval of the proposed settlement, as a federal court’s June 17, 2026 remand order describes it. Bayer’s release says that Monsanto will make declining, capped annual payments for up to 21 years, totaling up to $7.25 billion inclusive of payments already made, that the agreement contains no admission of liability or wrongdoing, and that the approval order is subject to appeal. The case therefore stands at this point: final approval granted on November 20, 2026, subject to appeal. The next dated step is set by Missouri’s appeal rules. Under Missouri Supreme Court Rule 81.05, a judgment becomes final 30 days after its entry if no timely authorized after-trial motion is filed, and Rule 81.04 requires a notice of appeal within ten days after that.

For anyone who used the product and was diagnosed with lymphoma, the practical questions are when money can move, what an appeal would change, and what remains for people who opted out after the Supreme Court’s June 25, 2026 ruling on warning-label claims. The discussion that follows is general in scope: it describes checks useful in comparable situations and makes no findings about Monsanto’s or Bayer’s situation.

I. What does final approval change, and what can still delay payment?

A. Treat the approval as a Missouri judgment with its own appeal clock

A class settlement binds people who never filed a lawsuit, so a court has to approve it before it takes effect. Missouri rewrote its class action rule with effect from January 1, 2026, in an order of the Supreme Court of Missouri dated June 30, 2025. The new Rule 52.08(e)(2) provides: “If the proposal would bind class members, the court may approve it only after a hearing and only on finding that it is fair, reasonable, and adequate.” The rule then lists what the judge must consider: whether the class representatives and class counsel adequately represented the class, whether the deal was negotiated at arm’s length, whether the relief is adequate in light of the costs, risks and delay of trial and appeal and the method of processing claims, and whether class members are treated equitably relative to each other. The Roundup class action was filed in February 2026, after that version took effect, and the settlement website lists a fairness hearing on September 14, 2026. The November 20 decision is the result of that process.

Approval and finality are not the same thing. Missouri’s Rule 74.01 defines when a judgment exists: “A judgment is entered when a writing signed by the judge and denominated ‘judgment’ or ‘decree’ is filed.” The first check for a class member, or for a lawyer advising one, is therefore the docket itself. Look for the signed writing, its title and the date on which it was filed, because the appeal clock runs from entry. A press release or a news story reporting the approval does not show which document was entered or when.

From entry, two Missouri rules govern timing. Rule 81.05(a)(1) states: “A judgment becomes final in a civil matter at the expiration of 30 days after its entry if no timely authorized after-trial motion is filed.” If such a motion is filed, Rule 81.05(a)(2) makes the judgment final at the earlier of two dates: 90 days after the last timely motion was filed, when motions not yet ruled are deemed overruled, or, if all motions have been ruled, the later of the ruling on the last motion and 30 days after entry. Rule 81.04(a) then sets the filing window: “No such appeal shall be effective unless the notice of appeal shall be filed not later than ten days after the judgment, decree, or order appealed from becomes final.” This article does not compute a calendar date, because the computation depends on the entry date of the signed writing and on any motion filed after it, which a reader should confirm on the docket.

Who may appeal is a separate question. Missouri’s appeal statute, section 512.020 of the Revised Statutes of Missouri, gives the right to “Any party to a suit aggrieved by any judgment of any trial court in any civil cause” and lists final judgments among the appealable decisions. The texts read for this article do not say whether a class member who objected, but never became a party, counts as a party for that purpose. That is a question for the Missouri appellate courts if an objector files a notice of appeal, and readers should not treat it as settled either way.

The settlement’s procedural history already shows that objectors have tried other routes. According to the remand order, ten objectors filed objections in the Missouri court on May 21, 2026, and removed the case to federal court the next day, calling themselves “Objector Defendants.” Both the class representatives and the defendant asked the federal court to send the case back. Judge Henry Edward Autrey of the Eastern District of Missouri granted both motions in King v. Monsanto Co., No. 4:26-CV-813 HEA (E.D. Mo. June 17, 2026). He relied on 28 U.S.C. § 1441(a), which provides that a civil action “may be removed by the defendant or the defendants,” and wrote in the remand order: “Removal of an action by people who are not defendants in the action is not authorized.” That ruling answers a federal removal question. It does not decide whether an objector may appeal in Missouri’s own courts. Monsanto’s published statement adds that on August 27, 2026, the Eighth Circuit dismissed the objectors’ attempted appeal of the remand ruling; the order itself was not read for this article.

Missouri’s new rule also addresses a familiar source of delay. Rule 52.08(e)(5)(B), in the same June 30, 2025 order, provides: “Unless approved by the court after a hearing, no payment or other consideration may be provided in connection with” withdrawing an objection or abandoning an appeal from a judgment approving the proposal. Any side deal to drop an appeal must therefore come back before the judge, in a hearing, rather than being settled privately.

Why does any of this matter to someone waiting for money? Because the settlement’s payment schedule is tied to appeals. Bayer’s November 20 release states that any appeal of the final approval order would pause further payments by Monsanto under the settlement until such appeals are exhausted. The settlement website describes the claimant’s side of the same timing: people already diagnosed are to register within 180 days after the court grants final approval, and to file a claim within 180 days after any appeals are resolved. When read on November 22, 2026, the site’s banner still said registration and claim submission were not open because final approval had not been granted, so the registration window should be confirmed on the site or with class counsel rather than assumed from the approval date alone. For a comparable situation in which a court ruling did not by itself put money in class members’ hands, see our analysis of whether the NFL Sunday Ticket lawsuit has a payout per person after the Ninth Circuit ruling.

B. Check how appellate courts have reviewed objections under the same factors

If an objector does appeal, what will the appellate court look at? Missouri’s appellate courts apply Missouri law, and federal decisions do not bind them. Still, the factors in Missouri’s new Rule 52.08(e)(2) repeat, with only drafting differences such as “attorney fees” for “attorney’s fees,” the factors in Federal Rule of Civil Procedure 23(e)(2), which also lets a court approve a binding proposal “only after a hearing and only on finding that it is fair, reasonable, and adequate.” Recent federal appellate decisions applying that text show what objectors have to establish, and how much deference the approving judge receives.

In In re Google Location History Litigation, No. 24-3387 (9th Cir. Aug. 26, 2026), the Ninth Circuit affirmed the final approval of a privacy class settlement over objectors who challenged its distribution method. The court stated its standard plainly: “We review a district court’s approval of a proposed class action settlement, including a proposed cy pres settlement distribution, for abuse of discretion.” It rejected the objectors’ argument that the trial judge had leaned on a presumption that settlements are fair, holding that the judge held a fairness hearing, weighed the objections and considered the Rule 23(e) factors, and that “The district court did not improperly apply a broad presumption of settlement validity to the entirety of its analysis.” The lesson for a pending objector appeal is concrete: an objector who wants to undo an approval generally has to show that the judge misapplied the factors or failed to address the objections, not merely that a different settlement would have been better.

The Eighth Circuit, whose territory includes Missouri’s federal courts, reached the same kind of result twice this year in the real estate commission litigation. In Burnett v. National Association of Realtors, No. 24-3444 (8th Cir. Aug. 19, 2026), the court affirmed approval of a nationwide settlement over several groups of objectors and described its review this way: “Only upon the clear showing that the district court abused its discretion will this court intervene to set aside a judicially approved class action settlement.” In the related appeal, Gibson v. National Association of Realtors, No. 24-3473 (8th Cir. Sept. 1, 2026), decided on September 1, 2026, the court adopted that analysis and repeated that “Due process is satisfied where class members received notice of the settlement proposal and were able to argue their objections to the district court.” Neither case involved a product injury, and neither binds a Missouri state court reviewing a state-court judgment. They show, however, that objections about notice, hearing procedure and the shape of a release are reviewed deferentially once a judge has held the hearing the rule requires.

Three practical checks follow from those decisions. First, an objection that was never filed by the deadline set in the notice is unlikely to be the basis of an appeal; the settlement website lists June 4, 2026, as both the objection and the opt-out deadline. Second, the written approval decision matters as much as the result, because appellate courts test whether the judge addressed each statutory factor and each non-frivolous objection. A class member trying to gauge the risk of delay should read the court’s findings on adequacy of representation, arm’s-length negotiation, the claims process and equitable treatment. Third, even an appeal that fails takes time. The Ninth Circuit decision above came more than a year after argument, and the Eighth Circuit’s two decisions came months after submission. Those figures describe those cases, not the Missouri timetable, but they illustrate why a filed appeal, if one is filed, is a reason to expect a pause rather than a quick payment.

II. Who can be paid under the settlement, and what remains for people outside it?

A. Confirm membership, category and documents before the claims window opens

Membership turns on exposure and timing. Bayer’s release describes the class as people who allege exposure to Roundup products before February 17, 2026, and who either have a medical diagnosis of non-Hodgkin lymphoma now or receive one within 16 years after the effective date of the agreement. The settlement website adds detail. It covers United States citizens and non-citizens living in the United States on March 4, 2026, who had contact with, inhaled, ingested or absorbed the products in the United States before February 17, 2026, because they applied them, paid for them or their application, directed or saw an application, or otherwise had reason to know they were exposed. Spouses, parents and dependent children can be derivative claimants, and executors or administrators can act for a deceased or incapacitated person. The site states that immigration status does not affect inclusion.

The site divides members into two subclasses. Subclass 1 covers people diagnosed with non-Hodgkin lymphoma as of March 4, 2026. Subclass 2 covers people who meet the exposure requirements but have not been diagnosed; they are bound by the settlement now and can claim compensation only if they are diagnosed later. For later diagnoses, the website says a claim must be filed within six years of diagnosis or before the 16th annual payment date. Those dates come from the settlement program as summarized on its website; the court-approved agreement and notice control if the summary and the documents differ, so the documents posted on the site are the ones to keep.

The amount depends on category and age at diagnosis. According to the settlement website, an occupational claimant is someone exposed for more than 80 hours in agricultural, industrial, turf or ornamental work who earned more than half of their income, or more than $15,000, from that work in at least one year, and the estimated award range shown for that category is $60,000 to $165,000. Residential claimants, typically homeowners who used the products around the house, are shown at $20,000 to $40,000, with an optional quick-pay amount of $7,700 to $14,500. For people diagnosed at age 78 or older, the site shows $10,000, or $6,000 under quick pay. The site also mentions additional payments for extraordinary circumstances, extra compensation for heavy home use and faster payment for extreme hardship. The program pays claims over 17 to 21 years, the website says, which is consistent with the capped annual payment structure described in Bayer’s release.

Proof drives the category. The website lists the kind of evidence expected for an occupational claim: employment records, payroll records, business licenses or tax records. Before registration opens, a claimant can assemble four groups of documents: the pathology or physician record showing the date and type of diagnosis, which also fixes the subclass; records of where and when the product was used, including purchase receipts, application logs or photographs; for occupational claims, the employment and income records that show the 80-hour and income thresholds; and, for derivative or representative claims, the marriage, birth, guardianship or probate documents that establish the relationship or the authority to act. Gathering them now costs nothing and avoids losing the 180-day registration window if no appeal is filed.

A claimant with a pending individual lawsuit should also check how the settlement treats it. Bayer’s release describes the program as resolving present and future claims regardless of the legal theory on which they are based. The settlement website’s own summary of the options states the trade-off: excluding oneself kept the right to file an individual lawsuit but meant receiving no money from the settlement, and the deadline to do so was June 4, 2026. The precise scope of what class members give up is defined by the release in the corrected settlement agreement posted on the settlement website, and that text, not a press summary, is what a court would apply.

B. For people who opted out, start from what the Supreme Court decided on warnings

People who excluded themselves by June 4, 2026, kept the right to sue on their own, but they now litigate under a different legal landscape. In Monsanto Co. v. Durnell, No. 24-1068 (U.S. June 25, 2026), the Supreme Court of the United States reversed a judgment of the Missouri Court of Appeals that had affirmed a jury award of more than $1 million to a Roundup user on a failure-to-warn theory. The opinion explains that EPA has repeatedly concluded that glyphosate is not likely to cause cancer, that it has not required a cancer warning on the label, and that federal law requires the manufacturer to use the label EPA approved. The Court held: “Because Durnell’s state tort claim would impose a pesticide labeling requirement ‘in addition to or different from’ the label required by EPA, FIFRA expressly preempts Durnell’s claim.” For an opt-out plaintiff, the direct consequence is that a claim built on the absence of a cancer warning on the federally approved label faces that holding.

The statutory basis is short. Section 24(b) of the Federal Insecticide, Fungicide, and Rodenticide Act, codified at 7 U.S.C. § 136v(b), provides: “Such State shall not impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under this subchapter.” The same section, in subsection (a), still allows a state to regulate the sale or use of a federally registered pesticide to the extent the regulation does not permit a sale or use the federal statute prohibits. Durnell addressed the failure-to-warn claim that was before the Court; the opinion’s own description of the case says that, as relevant there, the plaintiff brought a claim that a cancer warning should have been on the label. It also notes that EPA may change course in light of new information: “It is true that EPA may subsequently change course in light of new information or new analysis, and require an amended label and amended registration.” Whether particular non-label theories survive in a given case is decided by the courts handling those cases.

Legislative proposals do not change that picture unless they are enacted. A Congressional Research Service Legal Sidebar dated September 21, 2026 notes that “Congress has authority to amend FIFRA to expressly preempt or allow state failure-to-warn claims” and describes bills in the 119th Congress, including H.R. 9528, which would amend the preemption provision, and S. 2324, which would create a federal cause of action. These are proposals, not law. A reader deciding what to do now should rely on the statute as it reads today and on Durnell.

Preemption is not the only obstacle. An individual plaintiff must still prove that the product caused the disease, and federal courts apply a demanding gatekeeping standard to the expert evidence used for that purpose. In Engilis v. Monsanto Co., No. 23-4201 (9th Cir. Aug. 12, 2025), a case from the federal multidistrict litigation over the same herbicide, the Ninth Circuit affirmed summary judgment for the manufacturer after the trial judge excluded the plaintiffs’ only specific-causation expert, whose differential etiology had not reliably ruled out obesity as an alternative cause. The court confirmed that “a proponent of expert testimony must always establish the admissibility criteria of Rule 702 by a preponderance of the evidence and that there is no presumption in favor of admission.” Because the excluded opinion was the plaintiffs’ sole causation evidence, the case ended there; the court added that “we need not consider Monsanto’s alternative argument that Engilis’s claims are preempted by federal law.” For an opt-out plaintiff, the application is direct: a causation expert has to rule out the plaintiff’s other potential causes, as the obesity question in Engilis shows, with stated reasons and support in the medical record.

Trial results since Durnell point the same way, at least in the one case reported so far. Bayer’s release states that in the first Roundup trial after the Supreme Court’s decision, the trial court ruled the failure-to-warn claims preempted and a Missouri jury returned a defense verdict on October 29, 2026, on design defect, fraud and negligence claims. That is a single verdict described by one party; it is not an appellate holding and does not decide other cases, but it shows the burdens an opt-out plaintiff carries.

Limitation periods and the state law governing an individual claim are not addressed here, because the sources read for this article do not set them. An opt-out plaintiff should have a lawyer check, for the state where the claim would be filed, the limitations rule, the date the claim accrued and the effect of any earlier filing.

Conclusion

The November 20, 2026 approval is a decisive step, but money does not move on the strength of a press release. Under Missouri’s rules, the approval has to be entered as a signed judgment, it becomes final 30 days after entry absent an authorized after-trial motion, and any notice of appeal is due within ten days after that. According to the company’s release, an appeal would pause further payments until it is exhausted, and according to the settlement website, claims by people already diagnosed are filed within 180 days after any appeals are resolved. Recent federal appellate decisions applying the same fairness factors have deferred heavily to the judges who approved settlements, which matters if an objector appeals, although those decisions do not bind Missouri’s courts. Class members can use the waiting period to confirm their subclass and category and to collect diagnosis, exposure and employment records. People who opted out face a warning-label theory that the Supreme Court has held preempted and a causation burden that federal courts enforce strictly, so their next step is a claim-specific review of the facts and the governing state law.

📄 Official circular